Conditional animal models: A strategy to define when oncogenes will be effective targets to treat cancer

Seminars in Cancer Biology

Volumn 14, Issue 1, 2004, Pages 3-11

  Giuriato, Sylvie ^a   Rabin, Karen ^a   Fan, Alice C ^a   Shachaf, Catherine M ^a   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Mouse knockouts; MYC; Oncogenes; Tamoxifen system; Tetracycline regulatory system; Transgenic mice

Indexed keywords

BCR ABL PROTEIN; CRE ENZYME; CYTOSINE DEAMINASE; DIPHTHERIA TOXIN; DOXYCYCLINE; GENE PRODUCT; RECOMBINASE; SCATTER FACTOR RECEPTOR; TAMOXIFEN; TETRACYCLINE; THYMIDINE KINASE; UNCLASSIFIED DRUG; WNT1 PROTEIN;

BIOLOGICAL MODEL; CANCER RECURRENCE; CELL ONCOGENE; CYTOPATHOGENIC EFFECT; DNA VECTOR; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE THERAPY; GENETIC ENGINEERING; KNOCKOUT MOUSE; MOLECULAR INTERACTION; NONHUMAN; ONCOGENE MYC; ONCOGENE RAS; PROTEIN DOMAIN; REPRESSOR GENE; REVIEW; SUICIDE GENE; TARGET CELL; TISSUE SPECIFICITY; TRANSACTIVATION; TRANSGENIC MOUSE; TUMOR REGRESSION;

EID: 0742287062     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.11.002     Document Type: Article

References (57)

1. Van Dyke T., Jacks T. Cancer modeling in the modern era: progress and challenges. Cell. 108:2002;135-144.
2. Jonkers J., Berns A. Conditional mouse models of sporadic cancer. Nat. Rev. Cancer. 2:2002;251-265.
3. Felsher D.W. Opinion. Cancer revoked: oncogenes as therapeutic targets. Nat. Rev. Cancer. 3:2003;375-379.
4. Giuriato S., Felsher D.W. How cancers escape their oncogene habit. Cell Cycle. 2:2003;329-332.
5. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A. 89:1992;5547-5551.
6. Furth P.A., St. Onge L., Boger H., Gruss P., Gossen M., Kistner A.et al. Temporal control of gene expression in transgenic mice by a tetracycline- responsive promoter. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9302-9306.
7. Kistner A., Gossen M., Zimmermann F., Jerecic J., Ullmer C., Lubbert H. et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10933-10938.
8. Green E.A., Flavell R.A. The temporal importance of TNFalpha expression in the development of diabetes. Immunity. 12:2000;459-469.
9. Mayford M., Bach M.E., Huang Y.Y., Wang L., Hawkins R.D., Kandel E.R. Control of memory formation through regulated expression of a CaMKII transgene. Science. 274:1996;1678-1683.
10. Tremblay P., Meiner Z., Galou M., Heinrich C., Petromilli C., Lisse T.et al. Doxycycline control of prion protein transgene expression modulates prion disease in mice. Proc. Natl. Acad. Sci. U.S.A. 95:1998;12580-12585.
11. Ahmad A., Brinson M., Hodges B.L., Chamberlain J.S., Amalfitano A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy. Hum. Mol. Genet. 9:2000;2507-2515.
12. Littlewood T.D., Hancock D.C., Danielian P.S., Parker M.G., Evan G.I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1995;1686-1690.
13. Pelengaris S., Khan M., Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer. 2:2002;764-776.
14. Lakso M., Sauer B., Mosinger B. Jr., Lee E.J., Manning R.W., Yu S.H.et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6232-6236.
15. Orban P.C., Chui D., Marth J.D. Tissue- and site-specific DNA recombination in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6861-6865.
16. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis. 26:2000;99-109.
17. Saam J.R., Gordon J.I. Inducible gene knockouts in the small intestinal and colonic epithelium. J. Biol. Chem. 274:1999;38071-38082.
18. Utomo A.R., Nikitin A.Y., Lee W.H. Temporal, spatial, and cell type-specific control of Cre-mediated DNA recombination in transgenic mice. Nat. Biotechnol. 17:1999;1091-1096.
19. Holzenberger M., Zaoui R., Leneuve P., Hamard G., Le Bouc Y. Ubiquitous postnatal LoxP recombination using a doxycycline auto-inducible Cre transgene (DAI-Cre). Genesis. 26:2000;157-159.
20. Pao W., Klimstra D.S., Fisher G.H., Varmus H.E. Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Proc. Natl. Acad. Sci. U.S.A. 100:2003;8764-8769.
21. Edinger M., Cao Y.A., Hornig Y.S., Jenkins D.E., Verneris M.R., Bachmann M.H.et al. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur. J. Cancer. 38:2002;2128-2136.
22. Contag C.H., Bachmann M.H. Advances in in vivo bioluminescence imaging of gene expression. Annu. Rev. Biomed. Eng. 4:2002;235-260.
23. Ewald D., Li M., Efrat S., Auer G., Wall R.J., Furth P.A.et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science. 273:1996;1384-1386.
24. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
25. Xie W., Chow L.T., Paterson A.J., Chin E., Kudlow J.E. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene. 18:1999;3593-3607.
26. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell. 4:1999;199-207.
27. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24:2000;57-60.
28. Tichelaar J.W., Lu W., Whitsett J.A. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J. Biol. Chem. 275:2000;11858-11864.
29. D'Cruz C.M., Gunther E.J., Boxer R.B., Hartman J.L., Sintasath L., Moody S.E.et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7:2001;235-239.
30. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J.et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15:2001;3249-3262.
31. Wang R., Ferrell L.D., Faouzi S., Maher J.J., Bishop J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153:2001;1023-1034.
32. Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 109:2002;321-334.
33. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M.et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:2002;102-104.
34. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D.et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2:2002;451-461.
35. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell. 3:1999;565-577.
36. Gunther E.J., Moody S.E., Belka G.K., Hahn K.T., Innocent N., Dugan K.D.et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17:2003;488-501.
37. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 101:2003;2797-2803.
38. Meuwissen R., Linn S.C., van der Valk M., Mooi W.J., Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene. 20:2001;6551-6558.
39. Rane S.G., Cosenza S.C., Mettus R.V., Reddy E.P. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol. Cell Biol. 22:2002;644-656.
40. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.J., Downing J.R. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 1:2002;63-74.
41. Forster A., Pannell R., Drynan L.F., McCormack M., Collins E.C., Daser A.et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell. 3:2003;449-458.
42. Buchholz F., Refaeli Y., Trumpp A., Bishop J.M. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep. 1:2000;133-139.
43. Suzuki A., Itami S., Ohishi M., Hamada K., Inoue T., Komazawa N.et al. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res. 63:2003;674-681.
44. Moynahan M.E. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene. 21:2002;8994-9007.
45. Shibata H., Toyama K., Shioya H., Ito M., Hirota M., Hasegawa S.et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science. 278:1997;120-123.
46. Vooijs M., van der Valk M., te Riele H., Berns A. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse. Oncogene. 17:1998;1-12.
47. Langa F., Lafon I., Vandormael-Pournin S., Vidaud M., Babinet C., Morello D. Healthy mice with an altered c-myc gene: role of the 3′ untranslated region revisited. Oncogene. 20:2001;4344-4353.
48. Geng Y., Yu Q., Sicinska E., Das M., Schneider J.E., Bhattacharya S.et al. Cyclin e ablation in the mouse. Cell. 114:2003;431-443.
49. Chin L., DePinho R.A. Flipping the oncogene switch: illumination of tumor maintenance and regression. Trends Genet. 16:2000;147-150.
50. Harada N., Miyoshi H., Murai N., Oshima H., Tamai Y., Oshima M.et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res. 62:2002;1971-1977.
51. Lee E.J., Jameson J.L. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum. Gene. Ther. 13:2002;533-542.
52. Yoshimura I., Ikegami S., Suzuki S., Tadakuma T., Hayakawa M. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J. Urol. 168:2002;2659-2664.
53. Nagayama Y., Nishihara E., Iitaka M., Namba H., Yamashita S., Niwa M. Enhanced efficacy of transcriptionally targeted suicide gene/prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res. 59:1999;3049-3052.
54. Goto H., Osaki T., Kijima T., Nishino K., Kumagai T., Funakoshi T.et al. Gene therapy utilizing the Cre/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells. Int. J. Cancer. 94:2001;414-419.
55. Andreu T., Ebensperger C., Westphal E.M., Klenner T., Stewart A.F., Westhof A.et al. Self-deleting suicide vectors (SDSV): selective killing of p53-deficient cancer cells. Cancer Res. 61:2001;6925-6930.
56. Mizumoto M., Arii S., Furutani M., Mori A., Imamura M. A novel suicide gene therapy system for p53-mutated cells using a wild-type p53-specific promoter and Cre/loxP switch. Surg. Today. 32:2002;53-58.
57. Ueda K., Iwahashi M., Nakamori M., Nakamura M., Matsuura I., Ojima T.et al. Improvement of carcinoembryonic antigen-specific prodrug gene therapy for experimental colon cancer. Surgery. 133:2003;309-317.